Part 4/8:
The move toward MFN pricing resulted from persistent negotiations and exercised pressure on major pharmaceutical companies, notably Pfizer. Craig D. Volden, Pfizer's CEO, participated in the Oval Office meeting, approving this aligned pricing strategy, which ensures Americans pay comparable prices to other countries without demanding better terms.